Eli Lilly and Company
Other Study ID Numbers:
18558J1I-MC-GZBK ( Other Identifier: Master Protocol Eli Lilly and Company )J1I-MC-GSA2 ( Other Identifier: ISA Eli Lilly and Company )2023-503658-11-00 ( Other Identifier: EU Trial Number )
July 3, 2023 Key Record Dates
Last Update Posted:
August 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD:
Anonymized individual participant level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Study ProtocolStatistical Analysis Plan (SAP)Clinical Study Report (CSR)
a are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.